Finoriq research workspace
Lantheus Holdings, Inc. (LNTH) SEC Filings & Filing Highlights
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic. Review LNTH SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
- Company
- Lantheus Holdings, Inc. (LNTH)
- Ticker
- LNTH
- Market Cap
- $6.9B
- Latest Price
- $105.6
- Industry
- Diagnostics
Lantheus Holdings, Inc. (LNTH) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Lantheus Holdings, Inc. (LNTH).
| Event | Form | Date |
|---|---|---|
| Lantheus Reports First Quarter 2026 Financial Results and Provides Business UpdateLantheus Reports First Quarter 2026 Financial Results and Provides Business Update | 8-K2.02 | 2026-05-07 |
| The Annual Meeting of Shareholders of the Company was held on April 30, 2026. Set forth below i...The Annual Meeting of Shareholders (the “Annual Meeting”) of the Company was held on April 30, 2026. Set forth below is a brief description... | 8-K5.07 | 2026-05-01 |
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearAmendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 8-K5.03 | 2026-05-01 |
| As disclosed under Item 5.07, on April 30, 2026, the shareholders of Lantheus Holdings, Inc. (t...As disclosed under Item 5.07, on April 30, 2026, the shareholders of Lantheus Holdings, Inc. (the “Company”) approved the Company’s Amended... | 8-K5.02 | 2026-05-01 |
| The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated herei...The information set forth in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference | 8-K3.03 | 2026-05-01 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.